Alcohol Drinking Clinical Trial
Official title:
An Open-label, Randomized, Cross-over, Comparative Study of ALCOFILTRUM Dietary Food Supplement for Alleviating Alcohol Hangover Symptoms in Healthy Volunteers
The aim of this open-label, randomized, crossover, comparative pilot study is to assess efficacy and safety of the dietary food supplement ALCOFILTRUM in healthy volunteers who consume alcohol. Specifically the study will evaluate: - Efficacy of the intervention to alleviate hangover symptoms in participants who consumed alcohol, - Safety of intervention in participants who consuming alcohol. Participants will take four tablets of ALCOFILTRUM dietary food supplement 30 minutes before alcohol ingestion, while the control group will intake only alcohol drink.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | May 30, 2023 |
Est. primary completion date | March 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 25 Years to 45 Years |
Eligibility | Inclusion Criteria: - Healthy men aged from 25 to 45 years inclusive. - Body weight index of 18.5 to 30 kg/m2, with body weight of 60 kg to 100 kg. - Healthy volunteers should behave adequately, with coherent speech observed. - Available written Informed Consent for participation in this Study given by a healthy volunteer according to the effective laws. - Subjects with history of episodic intake of alcohol and episodic hangover symptoms. - Verified diagnosis "healthy": no chronic diseases in the history, no abnormal findings of lab tests and clinical investigations. Exclusion Criteria: - The Investigator's decision that a healthy volunteer is to be excluded in the interests of the volunteer. - Any serious adverse event occurring to a healthy volunteer and associated with intake of alcohol and/or the study product. - A healthy volunteer refusing to collaborate with the Medical Investigator or not complying with the Study procedure. - A healthy volunteer was enrolled into the Study with violation of the Clinical Study Protocol. - Any adverse events occurring to a healthy volunteer that, in a Medical Investigator's opinion, may endanger safety of a volunteer. - Positive urine opioid test. - Positive COVID-19 Ag Rapid Test. - Positive blood alcohol test judging by concentration of alcohol fumes in exhaled air. - 0.15 mg/L or higher content of alcohol fumes in exhaled air at the Screening Visit and at Visits 2, 3 prior to intake the first alcohol portion. |
Country | Name | City | State |
---|---|---|---|
Belarus | Clinical Emergency Hospital | Minsk |
Lead Sponsor | Collaborator |
---|---|
AVVA Pharmaceuticals Ltd. |
Belarus,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Incidence of Adverse Events [Safety and Tolerability] | Incidence rate of any adverse events. | 5 days | |
Other | Incidence of Serious Adverse events [Safety and Tolerability] | Incidence rate of any serious adverse events. | 5 days | |
Other | Arterial blood pressure [Safety and Tolerability] | Level of systolic and diastolic arterial blood pressure 1; 2; 3, 4, 12, 13 hours vs. baseline. | 13 hours | |
Other | Heart rate [Safety and Tolerability] | Hear rate 1; 2; 3, 4, 12, 13 hours vs. baseline. | 13 hours | |
Primary | 1-item overall hangover severity rating | Intensity of hangover symptoms in 12-13 hours after alcohol intake according to 1-item overall hangover severity rating. Score range is from 0 to 10, where higher scores mean more severe hangover symptoms. | 13 hours | |
Secondary | Schulte test | Attention focusing and work efficiency according to Schulte test. Measurement timepoints: baseline, 1, 4, 12, 13 hours. | 13 hours | |
Secondary | Romberg Stance test | Coordination and stability assessment in Romberg Stances. Measurement coordination and stability timepoints: baseline, 1, 4, 12, 13 hours. | 13 hours | |
Secondary | Mini Cog test | Psychoneurological status. Measurement timepoints: baseline, 1, 4, 12, 13 hours. | 13 hours | |
Secondary | Hangover Symptoms Questionnaire | Score of Hangover Symptoms Questionnaire and frequency of hangover symptoms. Score rating from 0 to 4 for 24 diferent symptoms, where higher scores mean higher severity of the symptoms. Measurement timepoints: baseline, 1, 4, 12, 13 hours. | 13 hours | |
Secondary | Blood Alcohol level | Concentration of ethanol in per mille. Measurement timepoints: baseline, 1, 4, 12 hours. | 12 hours | |
Secondary | Blood acetaldehyde level | Concentration of acetaldehyde in ng/mL. Measurement timepoints: baseline, 1, 4, 12 hours. | 12 hours | |
Secondary | C-reactive protein level | Blood concentration of C-reactive protein in mg/L. Measurement timepoints: baseline, 4, 12 hours. | 12 hours | |
Secondary | Bilirubin level | Blood concentrations of bilirubin and bilirubin fractions (direct and indirect) in umol/L. Measurement timepoints: baseline, 12 hours. | 12 hours | |
Secondary | Blood Inflamatory markers | Concentrations of TNF-alpha and 8-isoprostane in pg/mL. Measurement timepoints: baseline, 4, 12 hours. | 12 hours | |
Secondary | Liver enzyme markers | Blood concentrations of AST, ALT, ALP, GGT in u/L. Measurement timepoints: baseline, 12 hours. | 12 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05414344 -
A Brief Intervention for Alcohol Users With Interpersonal Trauma
|
N/A | |
Completed |
NCT05521906 -
Evaluation of PRYSHM for LGBTQIA2S+ Youth
|
N/A | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Withdrawn |
NCT04659278 -
Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use
|
N/A | |
Not yet recruiting |
NCT03632408 -
Hangover and Residual Zopiclone Effect on Spatial Perception
|
Phase 1 | |
Completed |
NCT02718508 -
An e-Parenting Skills Intervention to Decrease Injured Adolescents' Alcohol Use
|
N/A | |
Active, not recruiting |
NCT02629679 -
Sports, Education and Consumption of Substances in Adolescents
|
N/A | |
Completed |
NCT02945371 -
Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life
|
N/A | |
Completed |
NCT01553136 -
Varenicline Treatment of Alcohol Dependence in Smokers
|
Phase 2 | |
Completed |
NCT01442753 -
Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth
|
N/A | |
Completed |
NCT01081119 -
Brief Voluntary Alcohol and Drug Intervention for Middle School Youth
|
Phase 2 | |
Completed |
NCT04510116 -
Adults In The Making Prevention Trial
|
N/A | |
Completed |
NCT00289965 -
Substance Use Risk Education (SURE) Project
|
Phase 2 | |
Completed |
NCT00506753 -
Motivation and Skills for Delta-9-tetrahydrocannabinol/Ethanol (THC/ETOH+) Teens in Jail
|
N/A | |
Recruiting |
NCT05288790 -
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
|
Phase 2 | |
Recruiting |
NCT05620849 -
Young Adult Education on Alcohol & Health
|
N/A | |
Recruiting |
NCT03588754 -
Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking?
|
Phase 2 | |
Recruiting |
NCT04054466 -
Nursing Counseling to the Change of Behavior of Alcohol Consumption in Patients in HAART
|
N/A | |
Recruiting |
NCT06074341 -
TeleHealth Resources for IndiVidualizEd Goals (THRIVE) in Alcohol Recovery Study
|
N/A | |
Terminated |
NCT04596267 -
Pitolisant Effects on Alcohol Self-Administration in Heavy Drinkers
|
Phase 1 |